177Lu-LNC1010肽受体放射性核素治疗晚期神经内分泌肿瘤的前瞻性单中心单臂探索性研究
结果显示3/4级血液学毒性发生率为27%,客观缓解率为44.4%,疾病控制率为94.4%,中位无进展生存期为15.0个月,中位总生存期未达到。
要点
- 177Lu-LNC1010 3.3 GBq/周期治疗耐受性良好,3/4级血液学毒性27%。
- 客观缓解率44.4%,疾病控制率94.4%,中位PFS 15.0个月。
- 未记录到3级及以上肾毒性或肝毒性。
核心结论
- 177Lu-LNC1010以3.3 GBq/周期给药耐受性良好,安全性可接受。
- 客观缓解率和疾病控制率较高,且与PFS和OS改善正相关。
- 合适的患者选择和更早干预可能进一步优化治疗获益。
研究设计与样本
- 前瞻性、单中心、单臂、研究者发起的探索性试验。
- 患者接受最多4周期177Lu-LNC1010 PRRT,每周期3.3 GBq,间隔8周。
- 不良事件按NCI CTCAE v5.0分级,疗效按RECIST 1.1评价,Kaplan-Meier法估计PFS和OS。
主要发现
- 治疗相关3级或4级血液学毒性见于6例患者(27%)。
- 未记录到3级或以上肾毒性或肝毒性。
- 中位肿瘤吸收剂量为2.12(四分位距1.68-2.96)Gy/GBq。
- 18例可评估疗效:部分缓解8例(44.0%),疾病稳定9例(50.0%),疾病进展1例(5.6%)。
关键数值与推荐
- PRRT方案:177Lu-LNC1010 3.3 GBq/周期,最多4周期,间隔8周。
- 疗效评价标准:RECIST 1.1。
- 不良事件分级标准:NCI CTCAE v5.0。
- 中位肿瘤吸收剂量:2.12(IQR 1.68-2.96)Gy/GBq。
临床怎么用
- 对于经生长抑素类似物或酪氨酸激酶抑制剂治疗后进展的转移性NETs患者,可考虑177Lu-LNC1010 PRRT。
- 治疗期间需按CTCAE v5.0监测血液学毒性,3/4级血液学毒性发生率为27%。
- 本方案未观察到3级及以上肾毒性或肝毒性,但仍需常规监测。
- 合适的患者选择和更早干预可能进一步优化治疗获益。
局限性
- 疗效评估仅18例可评价,存在一定局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rapid radiopharmaceutical clearance limits the efficacy of peptide receptor radionuclide therapy (PRRT) for the treatment of advanced neuroendocrine tumors (NETs). In this prospective, single-center, single-arm, investigator-initiated trial, we evaluated the safety and efficacy of 177Lu-LNC1010-an optimized, long-acting somatostatin analog-in patients with progressive metastatic NETs. Methods: Twenty-two patients with unresectable, metastatic NETs and disease progression despite treatment with somatostatin analogs or tyrosine kinase inhibitors were enrolled in the study. Participants received up to 4 cycles of PRRT with 177Lu-LNC1010 (3.3 GBq/cycle) at 8-wk intervals. Adverse events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 5.0. The treatment response was evaluated using RECIST 1.1. Kaplan-Meier analysis was used to estimate progression-free survival (PFS) and overall survival (OS). Results: The patients (13 men, 9 women; median age, 50.5 y) received 69 PRRT cycles in total. Treatment-related grade 3 or 4 hematologic toxicities were observed in 6 patients (27%). No grade 3 or higher nephrotoxicity or hepatotoxicity was recorded. The median absorbed tumor dose was 2.12 (interquartile range: 1.68-2.96) Gy/GBq. Response after PRRT was assessed in 18 patients. A partial response was achieved in 8 patients (44.0%), stable disease in 9 (50.0%), and progressive disease in 1 (5.6%). The objective response rate was 44.4%, and the disease control rate was 94.4%. After a median follow-up of 21.0 mo, the median PFS was 15.0 mo, and the median OS was not reached. Conclusion: PRRT with 3.3 GBq/cycle of 177Lu-LNC1010 was well-tolerated and exhibited an acceptable safety profile. The objective response rate and disease control rate were high and positively correlated with improved PFS and OS. Appropriate patient selection and earlier intervention may further optimize the therapeutic benefit.
引用
- Guo W, Fan C, Chen Y, et al. A Prospective, Single-Center, Single-Arm, Exploratory Study of 177Lu-LNC1010 Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors. J Nucl Med. 2026. PMID: 42692826. doi:10.2967/jnumed.126.272607
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。